Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Transgene
  6. Summary
    TNG   FR0005175080

TRANSGENE

(TNG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
2.9(c) 2.92(c) 2.915(c) 2.91(c) 2.89(c) Last
68 571 47 134 79 109 29 113 32 083 Volume
-2.19% +0.69% -0.17% -0.17% -0.69% Change
More quotes
Financials
Sales 2021 11,1 M 13,4 M 13,4 M
Net income 2021 -27,1 M -32,8 M -32,8 M
Net cash position 2021 12,6 M 15,2 M 15,2 M
P/E ratio 2021 -9,03x
Yield 2021 -
Sales 2022 8,10 M 9,80 M 9,80 M
Net income 2022 -32,7 M -39,6 M -39,6 M
Net Debt 2022 19,6 M 23,7 M 23,7 M
P/E ratio 2022 -7,41x
Yield 2022 -
Capitalization 242 M 292 M 293 M
EV / Sales 2021 20,6x
EV / Sales 2022 32,3x
Nbr of Employees 139
Free-Float 34,7%
More Financials
Company
Transgene, part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The company's four lead clinical-stage programs are: TG4001 for HPV positive... 
More about the company
Ratings of Transgene
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about TRANSGENE
05/27BioInvent, Transgene Win US FDA Nod For Phase 1/2a Study of Cancer Vaccine
MT
05/27BIOINVENT INTERNATIONAL  : and Transgene receive IND approval from the U.S. FDA ..
AQ
04/28Global markets live: Microsoft, Apple, Tesla...
04/27TRANSGENE  : April 27, 2021 - Transgene reports business update and end Q1 2021 ..
PU
04/27LogicBio announces clinical and corporate updates
DJ
04/27TRANSGENE  : 1st quarter earnings
CO
04/12TRANSGENE  : April 12, 2021 - Transgene Announces Upcoming Investor Meetings
PU
04/09TRANSGENE  : April 9, 2021 - Transgene presents initial Phase I data of TG6002, ..
PU
04/07TRANSGENE  : April 7, 2021 - Availability of Preparatory Documents for the Combi..
PU
04/01TRANSGENE  : April 1, 2021 - Availability of Transgene's 2020 Universal Registra..
PU
04/01TRANSGENE  : Report
CO
03/30SGS  : to Support Selecta Biosciences, AskBio's Phase One Trial for Genetic Diso..
MT
03/18PRESS RELEASE  : Antion Biosciences Launches Novel Cell and Gene-engineering Pla..
DJ
03/17TRANSGENE BIOTEK  : in Pact to Provide Oral, Nasal Formulations for COVID-19 Vac..
MT
03/10TRANSGENE  : Expands Phase II Clinical Trial of Therapeutic Vaccine TG4001 in Co..
BU
More news
News in other languages on TRANSGENE
06/09STOCK MARKET PARIS : Une veillée d'armes un peu léthargique
06/09EN DIRECT DES MARCHES  : STMicroelectronics, Renault, Airbus, Compagnie des Alpe..
06/08TRANSGENE  : 8 juin 2021 - Transgene renforce les droits de propriété intellectu..
05/27STOCK MARKET PARIS : La sieste n'a pas l'air finie
05/27EN DIRECT DES MARCHES  : Kering, Dassault Systèmes, Airbus, HSBC, Ford, GlobalFo..
More news
Chart TRANSGENE
Duration : Period :
Transgene Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TRANSGENE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 3,85 €
Last Close Price 2,89 €
Spread / Highest target 55,7%
Spread / Average Target 33,2%
Spread / Lowest Target 10,7%
EPS Revisions
Managers and Directors
NameTitle
Hedi Ben Brahim Chairman & Chief Executive Officer
Jean-Philippe Del Chief Financial Officer
Eric Quéméneur Chief Scientific Officer & Executive VP
Hemanshu Shah VP-Medical Affairs & International Development
Maud Brandely VP-Clinical Operations & Regulatory Affairs
Sector and Competitors
1st jan.Capitalization (M$)
TRANSGENE75.36%292
GILEAD SCIENCES, INC.18.04%86 250
WUXI APPTEC CO., LTD.30.07%66 799
BIONTECH SE192.63%57 615
REGENERON PHARMACEUTICALS8.78%54 424
VERTEX PHARMACEUTICALS-18.33%49 966